{"schema_version":"secwatch.filing_event.v1","accession":"0001398733-26-000020","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2026-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.987768+00:00","generated_at":"2026-05-15T09:28:11.699132+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aquestive Therapeutics appoints new CLO/ CCO; Braender steps down as CLO","bullets":["Lori Braender steps down as CLO and CCO effective April 2, 2026; remains Corporate Secretary.","Thomas Zalewski appointed CLO and CCO effective April 2, 2026; former Partner at Day Pitney.","Zalewski receives inducement grant of 100k RSUs and 75k options, vesting over 3 years.","Braender eligible for severance payments and accelerated vesting under separation agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001398733-26-000020","json":"https://secwatch.observer/filing/0001398733-26-000020.json","markdown":"https://secwatch.observer/filing/0001398733-26-000020.md","text":"https://secwatch.observer/filing/0001398733-26-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000020/0001398733-26-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000020/aqst-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:28:11.699132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}